Barrington analyst Michael Petusky maintained a Hold rating on Anika Therapeutics (ANIK) today. The company’s shares closed last Tuesday at $35.75.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 4.0% and a 48.6% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Merit Medical Systems, and US Physical Therapy.
The the analyst consensus on Anika Therapeutics is currently a Hold rating.
See today’s analyst top recommended stocks >>
Based on Anika Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $30.68 million and GAAP net loss of $7.71 million. In comparison, last year the company earned revenue of $30.42 million and had a net profit of $9.44 million.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANIK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.